Not Tagged
spdr s&p biotech,ishares biotechnology
['solid tumor', '$ibb', '$xbi']
$bcel atreca's atrc-101 shows promise in ongoing phase 1b study for patients with select advanced solid tumors, as presented at asco 2023 annual meeting oral abstract session. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt